Page 7 - மாற்றத்தக்கது மூத்தவர் குறிப்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of . Apellis Pharmaceuticals, Inc.July 8, 2021 GMT WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of these exchange agreements, the holders have agreed to exchange with Apellis approximately $198.6 million in aggregate principal amount of Notes held by them for (i) 4,530,431 shares of Apellis’ common stock, which is equal to 22.8065 shares per $1,000 principal amount of Notes exchanged plus (ii) an additional number of shares of Apellis’ common stock per $1,000 principal amount of Notes

United statesTracy vineisExchange commissionApellis pharmaceuticals incConvertible senior notesSecurities actPrivate securities litigation reform actApelli quarterly reportஒன்றுபட்டது மாநிலங்களில்பரிமாற்றம் தரகுமாற்றத்தக்கது மூத்தவர் குறிப்புகள்பத்திரங்கள் நாடகம்ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம்